ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 10,921 shares, a decline of 48.1% from the January 29th total of 21,029 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average trading volume of 17,953 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 17,953 shares, the short-interest ratio is currently 0.6 days. Approximately 3.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. Csenge Advisory Group bought a new position in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,421 shares of the company’s stock, valued at approximately $163,000. Csenge Advisory Group owned approximately 6.54% of ProShares UltraShort Nasdaq Biotechnology as of its most recent SEC filing.

ProShares UltraShort Nasdaq Biotechnology Trading Up 1.4%

NASDAQ BIS opened at $8.56 on Friday. The company’s 50 day simple moving average is $8.94 and its two-hundred day simple moving average is $10.94. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $8.31 and a 1 year high of $25.87.

ProShares UltraShort Nasdaq Biotechnology Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Wednesday, December 24th were issued a $0.1026 dividend. The ex-dividend date of this dividend was Wednesday, December 24th. This represents a $0.41 annualized dividend and a dividend yield of 4.8%.

About ProShares UltraShort Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.